Federal Circuit invalidates Bayer’s Yaz patent

Several competitors to resume selling generic versions of the contraceptive

Bayer AG is facing more problems related to its Yaz contraceptive, after the Federal Circuit invalidated the company’s patent on the birth control pill.

A Nevada district court Bayer’s patent, which dealt with a dosing regimen for the contraceptive, in March 2012. But, on appeal, the generic drugmakers Watson Pharmaceuticals Inc., now known as Actavis Inc.; Sandoz Inc., a unit of Novartis International AG; and Lupin Ltd. argued that the claims in Bayer’s patent were obvious and that the lower court had overlooked prior art when reaching its decision. The Federal Circuit agreed and reversed the district court’s ruling.

Alanna Byrne

Bio and more articles

Join the Conversation

Advertisement. Closing in 15 seconds.